pd targets for voriconazole and posaconazole Severe asthma with fungal sensitisation and allergic bronchopulmonary aspergillosis encompass  (voriconazole and posaconazole)  inflamm allergy drug targets.
{"Image DocumentName": "Voriconazole Interactions Affecting Pharmacokinetics/Dynamics of Other Drugs", "Image ImageDescription": "(Enzyme) Effect. Management. Warfarin. (CYP 2C9) Inhibits primary metabolic pathway, increases PD effect by 41% Monitor INR and adjust dose accordingly. Immunosuppressants. (3A4) \u2022 Cyclosporin. \u2022 Tacrolimus. \u2022 Sirolimus. \uf0e9 Cmin 248%, AUC 70% \uf0e9 Cmin. Reduce dose by 50%, monitor. Reduce dose by 33%, monitor. Contraindicated. Miscellaneous. (2C9, 3A4) \u2022 Phenytoin. \u2022 Omeprazole. \u2022 Prednisolone. \u2022 Rifabutin. \uf0e9 Cmax 70%, AUC 80% \uf0e9 Cmax 2.5 fold, AUC 3.8 fold. \uf0e9 AUC 13-30% \uf0e9 AUC, 2-fold. Monitor phenytoin levels. Reduce dose by 50% Monitor. Voriconazole may also increase the plasma concentrations of several drugs including benzodizepines, calcium channel blockers, HMG-CoA reductase inhibitors, vinca alkaloids, busulfan, cyclophosphamide sulfonylureas, protease inhibitors, NNRTI\u2019s, sirolimus, quinidine and pimozidine, however, published studies are lacking.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}